Business Wire

EGLE Therapeutics Strengthens its Board of Directors with the Appointment of Michel Detheux, Ph.D., as Independent Chairman Board Member, and with the Appointment of Mojgan Hossein-Nia, Ph.D. as Board Member Representative of Takeda Ventures

Share

EGLE Therapeutics, a clinical-stage biotechnology company uniquely positioned to advance the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, announced today the appointment of Michel Detheux Ph.D, as Chairman of the Board and Independent Board Member, and Mojgan Hossein-Nia as Director representative of Takeda Ventures.

“We are thrilled to welcome Michel Detheux and Mojgan Hossein-Nia to our Board of Directors. Michel and Mojgan’s expertise and outstanding track record will be invaluable to Egle as we advance our clinical pipeline of novel therapies addressing the unmet medical need of patients with advanced cancer and autoimmune diseases.Their expertise in the field of oncology and their experience are instrumental for us to successfully execute on our strategic priorities,said Vincent Brichard, M.D., EGLE’s Interim CEO and Board member.

“With the role of regulatory T cells becoming clearer in oncology and auto-immunity, I am excited to join the Board of Egle in order to help the team to move their differentiated pipeline toward a clinical proof of concept and help patients with innovative drugs targeting IL-2,” said Michel Detheux, independent chairman at Egle and CEO of iTeos Therapeutics.

I am excited to join the Board of Egle in order to help the team strategize and continue to advance their pipeline to help patients in areas of unmet needs, said Mojgan Hossein-Nia, Board Member at Egle Therapeutics.

Michel Detheux, Ph.D, Michel has held the role of Chief Executive Officer at iTeos Therapeutics since the company’s inception in 2012. During his tenure, Michel has led the company from its origins to NASDAQ listing, raising $335MM in 2020 through a crossover round and IPO. More recently, he spearheaded the strategic collaboration with GlaxoSmithKline in 2021 to co-develop and co-commercialize iTeos’ differentiated anti-TIGIT antibody for a total value of $2B. He previously served as a director at Ludwig Cancer Research and worked in various scientific and business development roles at Ogeda (f/k/a Euroscreen).

Dr. Detheux holds a degree of Bio-engineer and a Ph.D. in Biochemistry from Université Catholique de Louvain, and a business certificate from Solvay Business School.

Mojgan Hossein-Nia, Ph.D., Mojgan is the Head of R&D Global Portfolio Strategy and Strategic Finance, Research and Development at Takeda. She joined the company in September 2017 and currently directs portfolio strategy and management across all therapeutic areas facilitating investment decisions and overseeing R&D governance process. Additionally, she manages enabling capabilities that support portfolio management including the center of operational performance and integrated portfolio/finance digital solutions. In previous roles, she led the R&D investor relations group and built up the R&D Partnership Office, which was created to manage the overall health of R&D’s pipeline partnerships and their integration into R&D processes.

Before joining Takeda, Mojgan worked at Novartis Pharmaceuticals, building and leading multiple global functions across R&D. Mojgan’s career spans over 30 years, comprising dedicated roles in development outsourcing, global program leadership and project management, business development & licensing, and across multiple therapeutic areas including cardiovascular, metabolism, and cell & gene therapies.

Dr. Hossein-Nia holds a B.Sc, and Ph.D. in biochemistry from University of London, UK, and a diploma in pharmaceutical medicine from University of Surrey, UK.

About Egle Therapeutics SAS (Egle)

Egle Therapeutics is a biotechnology company focused on developing immunotherapies targeting suppressive regulatory T cells. Egle is leveraging a proprietary discovery platform to unveil novel Treg specific targets and to develop innovative Treg-focused drug candidates for oncology and autoimmune diseases. Egle aspires to advance toward the clinic its most advanced drug candidates, EGL-001 (a potential best-in-class Treg-selective anti-CTLA4-IL-2m) and EGL-003 (non-targeted IL-2 Treg engager), which are currently in IND-enabling studies.

Find out more at www.egle-tx.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240912516511/en/

Contacts

contact@egle-tx.com / 0033 (0)1 86 64 08 57

contact@egle-tx.com / 0033 (0)1 86 64 08 57
investor.relations@egle-tx.com / 0033 (0)1 86 64 08 57

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

teamLab Planets TOKYO Reveals Entirety of the Newly Expanded Area, Featuring “Catching and Collecting Forest” and “Athletics Forest”. Opening January 2221.1.2025 18:00:00 CET | Press release

The educational projects “Catching and Collecting Forest,” “Athletics Forest,” and “Future Park” in the new area will feature over 20 artworks A new large-scale Athletics Forest and more artworks will open at teamLab Planets TOKYO DMM in Toyosu, Tokyo (teamLab Planets) on January 22, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250120453018/en/ teamLab, Catching and Collecting Extinct Forest (c) teamLab - There are various extinct animals that live in this Extinct Forest. When you move close to the animals or touch them, they will run away or turn to face you. teamLab Planets increases its area by 1.5 times, creating an extensive new space to introduce teamLab’s educational projects. The new additions include Athletics Forest, a complex, multi-dimensional creative athletic space; Catching and Collecting Extinct Forest where visitors can capture and study extinct animals; and Future Park, a collaborative space for co-

Tecnotree Secures Multi-Million Dollar Win with Tier-1 US Telecom Operator, Accelerating Digital Transformation for the Value Segment21.1.2025 16:37:00 CET | Press release

Tecnotree OYJ, a leading provider of digital business support systems and transformation solutions for the telecom industry, today announced a landmark multi-year, multi-million dollar agreement with a Tier-1 US telecom operator. This collaboration that was announced earlier in 2024 with a leading Global Systems Integrator, further solidifies Tecnotree's position as a trusted partner for operators navigating the complexities of digital transformation in the fast-evolving landscape. This significant win represents a major step forward in Tecnotree's mission to deliver cutting-edge digital solutions that drive unparalleled efficiency and enhance customer experiences. Tecnotree will deploy its advanced digital solutions suite, enhanced with our intelligent catalogue empowering the operator to launch innovative services, accelerating time to value. Tecnotree’s partnership with TM Forum, specifically its leadership in adopting TM Forum’s Open Digital Architecture (ODA) and achieving Diamond

Brand Finance Global 500 2025: Apple Is the Most Valuable Brand in the World, NVIDIA Enters Top Ten21.1.2025 16:22:00 CET | Press release

Apple is once again the world’s most valuable brand. Brand Finance, the world’s leading brand valuation consultancy, values Apple’s brand at USD574.5 billion, ahead of second-placed Microsoft (USD461 billion). According to Brand Finance’s research, four out of the five most valuable brands in the world are technology brands: Apple: brand value of USD574.5 billion, up 11% from 2024 Microsoft: USD461.1 billion, up 35% Google: USD413.0 billion, up 24% Amazon: USD356.4 billion, up 15% Walmart: USD137.2 billion, up 42% Brand Finance also analysed what brands have grown the most since 2020, plus TikTok – although Brand Finance began valuing the brand in 2022, its 79% growth in four years puts it in the same league as the other high-growth brands. TikTok/Douyin: USD105.8 billion, up from USD59.0 billion (in 2022) DraftKings: USD5.1 billion, up from USD18 million FanDuel: USD7.0 billion, up from USD56 million NVIDIA: USD87.9 billion, up from USD4.7 billion AMD: USD11.0 billion, up from USD1.4

HCL Group and UpLink Announce Winners of ‘Tackling Water Pollution Challenge’ Under the Aquapreneur Innovation Initiative21.1.2025 16:18:00 CET | Press release

10 Aquapreneurs selected from over 270 applicantsWinners showcased innovations from PFAS destruction, household filtration to nature-based water treatmentFinancial support of CHF 1.75 million available to scale initiativesAquapreneur Innovation Initiative: CHF 15 million commitment to global water challenges HCL Group, a leading global conglomerate, and UpLink, the World Economic Forum’s early-stage innovation initiative, have announced the winners of the 'Tackling Water Pollution Challenge,’ the third in a series of five challenges under the five-year, CHF 15 million Aquapreneur Innovation Initiative launched by HCL Group. The announcement marks a significant step in the ongoing mission to address global water challenges through groundbreaking innovation and entrepreneurship. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250121986084/en/ Roshni Nadar Malhotra, Chairperson of HCL Group, announces the winners of ‘Tackling Wa

Tacton Launches Connect to Anything, Powered by Workato, Simplifying Integration for Manufacturers21.1.2025 15:06:00 CET | Press release

Tacton, a global leader in Configure, Price, Quote (CPQ) software and leading SaaS platform simplifying sales and configuration processes for manufacturers of complex products, today announced the launch of its Connect to Anything integration capability, powered by Workato, the leading enterprise orchestration platform. This innovative solution transforms how manufacturers integrate Tacton CPQ into their digital ecosystems, enabling seamless connections to over 600 enterprise applications, including CRM, ERP, PLM, PIM, and analytics tools. Manufacturers often face costly inefficiencies from data silos and integration roadblocks as IT teams struggle to keep pace with complex connections. The stakes are high: poor data quality costs organizations an average of $12.9 million annually, according to Gartner’s® 2020 Magic Quadrant™ for Data Quality Solutions. Connect to Anything solves this challenge by making it simple to connect data across applications without heavy reliance on IT. With p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye